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Michael Trauner⇑Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, AustriaThe EASL Recognition Award has been created by our Association
to honor men and women who have shaped European Hepatol-
ogy as scientists, physicians and teachers. In this regard, Peter
Jansen matches every criteria for such an illustrious award. Peter
was born in March 1946 in Hertogenbosch, The Netherlands. In
1975, he obtained his PhD in Pharmacology from the Radboud
University Nijmegen and in 1977 his MD from the same Univer-
sity. This strategy in obtaining his academic degrees indicates
that Peter approached his aims slightly differently, with his
own vision of becoming a physician scientist and a scientiﬁc phy-
sician. Peter became initially infected by the research virus as a
student during a Summer Research Lab visit with Norman Javitt
in Upstate New York in 1967 where he cannulated the bile ducts
of rats in a project on bilirubin metabolism. From 1973 to 1976
Peter was trained as a research fellow at the Albert Einstein
College of Medicine in New York, USA, which at that time was al-
ready one of the places to be in liver research. There, he worked
in the laboratory of Win Arias, who was extremely inﬂuential as a
role model for Peter’s future scientiﬁc career. Both are still con-
nected by a close personal friendship and share many common
interests beyond science. Many of us would consider Peter Jansen
as the European counterpart of Win Arias, not only through their
common interests in biliary physiology and pathophysiology, but
even more by their creative and innovative approaches in
addressing new research questions and solving tricky problems.
The New York years were also very important for Peter’s young
and growing family. Peter was accompanied by his charming wife
Tineke and two of their three children were born during that time
in the United States. Apart from Peter’s scientiﬁc progress and
success during his time abroad, his family had a wonderful time
while making longlasting friendships with many international
colleagues such as Jayanta and Namita Roy Chowdhury and the
late Marcos Rojkind.
After returning from the States, Peter continued his career in
the Netherlands and moved through the academic ranks in Nijm-
engen before he was recruited by Prof. Guido Tytgat in 1986 as
Associate Professor to the Amsterdam Medical Center, where he
shaped the Liver Unit. In 1993, Peter was appointed Full ProfessorJournal of Hepatology 20
⇑ Address: Division of Gastroenterology and Hepatology, Department of Internal
Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, A-1090
Vienna, Austria. Tel.: +43 1 40400 4741.
E-mail address: michael.trauner@meduniwien.ac.atand Chair of Gastroenterology and Hepatology at the University of
Groningen, fromwhere he returned to Amsterdam in 2003 as Pro-
fessor and Head of the Liver Unit. As Division Chief and Liver Unit
Head, Peter has shaped and led the liver programs in Groningen
and Amsterdam and brought them both to the highest interna-
tional level as we know them today. Peter is a much sought after
visiting professor around the globe, respected editor, and has a list
of very impressive publications, with many of his articles pub-
lished in the most prestigious journals of our discipline.
A few words must be said of Peter Jansen, the man. Actually, it
is already all in his ﬁrst name if you take it as an acronym.
- P as in brilliant physician scientist, bridge builder, a creative
thinker who is able to translate clinical problems into basic
research questions and answer them.
- Enthusiastic and energetic, driven by an immense curiosity.
- T as in tough, he is very charming but can be tough as nails
when it comes to taking scientifc challenges and solving clin-
ical problems of his patients, he is a great team player, shaping
research consortia to solve tricky questions.12 vol. 57 j 241–243
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- Emphatic towards his patients and colleagues.
- Role model, so it’s all in Peter’s ﬁrst name – he is a role model
physician scientist!
Clearly, such personal attributes were bound to result in sci-
entiﬁc excellence. Peter has made landmark contributions unrav-
eling the molecular mechanisms of jaundice and cholestasis. His
discoveries have had a major impact on the ﬁeld, although I have
to admit that I may be biased in my judgement as a bile aﬁcio-
nado. The work of Peter and his colleagues on bilirubin glucuron-
idation and transport into bile paved the path for our
understanding of the molecular and genetic basis of Gilbert’s
and Crigler–Najjar syndrome [1–5], his work elucidated the bili-
rubin and organic anion transport defects in a rat model explain-
ing Dubin–Johnson syndrome [6–9] and jaundice of sepsis [10]. In
addition, he identiﬁed the principal mechanisms (e.g., multidrug
resistance-related protein 1) which allow rescue of the liver and
tumor cells from toxic compound overload [11]. His equally
important later work uncovered the spectrum of hereditary bile
salt export pump defects ranging from progressive familial intra-
hepatic cholestasis (PFIC) to benign recurrent intrahepatic chole-
stasis (BRIC) type 2 [12–14]. More recent work has helped
understand the role of ﬁbroblast-growth factor (FGF) 19 as novel
bile acid-induced hormone in the enterobiliary tract [15,16], the
newmetabolic role of bile acids and FGF-19 in non-alcoholic fatty
liver disease [17,18], as well as micro RNAs in liver cancer [19].
This broad and impressive spectrum of scientiﬁc inquiry is typical
of Peter Jansen, who has always searched for new challenges and
tasks to take on.
These discoveries in biliary (patho) physiology were discussed
with great passion at the Hochhausen Meetings where bile aﬁcio-
nados met in a modest but very familial and cordial atmosphere,
with Peter being always in the center. The more lucky among us
met at more exotic places such as Bora Bora – French Polynesia or
the Falk Meetings – Peter always managed to be at both and pre-
sided and chaired many of them.
As a highly successful academic mentor, Peter would give two
main lines of advice to young and aspiring scientists. First, get
abroad and get exposed to new thoughts and ideas, and second,
make a good couple with a science partner! As an academic men-
tor Peter took his own advice seriously and – probably heavily
inﬂuenced by the functional anatomy of the bile secretory appa-
ratus – made couples – I am tempted to say hepatocyte couplets
– with excellent basic scientists such as Ronald Oude Elferink,
Michael Müller and Han Moshage, who in the meantime have
become leaders of their own ﬁeld as full professors and depart-
ment chairs. More recent coworkers include Klaas Nico Faber
and Frank Schaap who are ready to continue the legacy of Peter,
together with Ulrich Beuers who has recently succeeded Peter as
Professor and Head of the Liver Unit in Amsterdam. Peter is
equally proud of his 24 PhD students who researched a broad
range of topics beyond transport and cholestasis, such as viral
hepatitis, fatty liver disease, inﬂammatory bowel disease, liver
transplantation and liver cancer.
Peter is also a very caring physician, who is loved and admired
by his patients. He is not only an excellent hepatologist in his
own subspecialty and research area (e.g. taking care of his Crigler
Najjar patients), but his clinical work encompasses the whole
spectrum of Clinical Hepatology. He is a complete hepatologist.
His empathy for patients and vision for academic medicine are
best reﬂected by quoting him from one of his papers which242 Journal of Hepatology 201originated just around the turn of the last millennium: ‘‘The
future of university-based research is uncertain. The staggering costs
of research and limited career possibilities may force universities to
the limited task of higher education, with as a result biotech compa-
nies, shareholders and corporate ﬁnance ruling the scientiﬁc waves
in the next century. The 21st century patient will know the way in
cyberspace and will go shopping for the best doctor, for the best
treatment and for the best, or friendliest, hospital’’ [20].
His deep understanding of our discipline and Medicine as a
whole became also evident when Peter served our Association
as Secretary General (1992–1993), and more recently as Educa-
tional Councilor (2007–2011). He was a visionary councilor and
ambassador for our society acting with much oversight and great
diplomacy. With his genuine interest in organizing educational
programs worldwide, he opened EASL towards Asia and South
America and was instrumental for making our Association to
what it has become today – a more international liver society.
Apart from being a successful physician scientist, he is also a
profoundly and widely educated person and family man. He is a
loving father of 3 children (2 girls, 1 son) and 5 grandchildren
who were all raised in the international spirit of the Jansen fam-
ily. Peter and his charming wife Tineke make a power couple for
now more than 44 years. Peter enjoys outdoor activities such as
golf and sailing, where he can exercise his natural born leader-
ship as skipper. He also loves to travel, exploring new countries
and cultures with great curiosity. When observing nature, Peter
can be as dedicated and meticulous in his hobbies as he is as a
scientist. So in a way, the private man Peter Jansen is very much
alike the physician scientist Peter Jansen whom we respect and
admire so much.
All of us who know Peter well enough, are fully aware that
formalities such as his recent retirement will not stop him. We
hope for the beneﬁt of the liver community that he will continue
his inspiring and innovative work for many more years in excel-
lent health and congratulate him with all our hearts with this
EASL recognition award 2012 for his eminent contributions to
the ﬁeld of Hepatology.
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